FDA Approves Rivfloza™ (nedosiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
October 2, 2023Hospira, Inc. Issues a Voluntary Nationwide Recall for 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due to the Potential for Presence of Glass Particulate Matter
October 2, 2023October 2, 2023 - Cyclopharm Limited announced the company has received U.S. Food and Drug Administration (FDA) approval to commence commercial sales of Technegas ® in the US market. The approval opens for Cyclopharm the single largest market for Technegas globally, and one which the company estimates to be initially worth approximately $180 million annually for the diagnosis and management of Pulmonary Embolism (PE).
- Strong pre-existing demand expected to drive sales momentum for an immediate US wide rollout.
- Approval allows for broad use of Technegas, supporting wider future indications across other respiratory disease states including Chronic Obstructive Pulmonary Disease (COPD), Asthma, Long COVID and lung cancer.